Phaseline

Targets › HPV

HPV: drug programs, companies and trials

9 programs from 7 companies in 10 trials: 5 Phase 2, 3 Phase 3, 2 Phase 4; Oncology, Infectious disease, Vaccines; next expected readout Mar 2027.

Open in Phaseline: the race on HPV, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Karolinska InstitutetGardasil 9
Nonavalent human papillomavirus (HPV) vaccine
HPVPhase 4Incident HPV16, 18, 31, 33, 45, 52 or 58 InfectionDec 2027
Miriam ElfströmGardasil9
Recombinant HPV vaccine (types 6, 11, 16, 18, 31, 33, 45, 52, 58)
HPVPhase 4HPV InfectionDec 2027
London School of Hygiene and Tropical Medicinebivalent HPV vaccine
bivalent HPV vaccine targeting HPV types 16 and 18
HPVPhase 3Human Papilloma VirusMar 2027
London School of Hygiene and Tropical Medicinenonavalent HPV vaccine
nonavalent HPV vaccine targeting HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58
HPVPhase 3Human Papilloma VirusMar 2027
National Vaccine and Serum Institute, China11-valent recombinant human papillomavirus vaccine (Hansenula polymorpha)
Recombinant HPV vaccine covering 11 HPV types
HPVPhase 3HPV InfectioNJun 2028
International Vaccine InstituteOSP:rTTHc Cholera Conjugate Vaccine (CCV)
Bivalent HPV vaccine
HPVPhase 2Cholera Vaccination; HPV VaccineMar 2027
Michael K. GibsonTA-HPV
Human papillomavirus tumor antigen vaccine
HPVPhase 2Metastatic Oropharyngeal CarcinomaSep 2027
Michael K. GibsonpBI-11
DNA plasmid vaccine encoding HPV antigens that promotes antibody, cytotoxic T cell, and pr
HPVPhase 2Metastatic Oropharyngeal CarcinomaSep 2027
Centre Oscar LambretHuman Papillomavirus 9-valent Vaccine, Recombinant
9-valent HPV vaccine targeting HPV types 6, 11, 16, 18, 31, 33, 45, 52, 58
HPVPhase 2Cervical LesionOct 2028

Conditions

Metastatic Oropharyngeal Carcinoma (2) Human Papilloma Virus (2) Incident HPV16, 18, 31, 33, 45, 52 or 58 Infection (1) Cervical Lesion (1) Cholera Vaccination (1) HPV Vaccine (1) HPV Infection (1) HPV InfectioN (1)

Modalities

other (4), protein or peptide (3), mixed (2)

Companies

Michael K. Gibson (2) London School of Hygiene and Tropical Medicine (2) Karolinska Institutet (1) Centre Oscar Lambret (1) International Vaccine Institute (1) Miriam Elfström (1) National Vaccine and Serum Institute, China (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.